ProPhase Labs, Inc. (PRPH) - Dilution Analysis

10-K filing | 14.0M shares outstanding

8-K filing: ProPhase Labs, Inc. entered into a Stock Purchase Agreement with Generating Alpha Ltd. for up to $10,000,000 of equity capital, issuing 549,105 shares of common stock and a warrant to acquire up to 240,369 shares of common stock as a commitment fee.

10-Q filing | 46.2M shares outstanding

S-1 filing: This S-1 filing registers shares underlying note conversions and warrant exercises, while also providing information about ProPhase Labs, its business, and various corporate developments.

8-K filing: ProPhase Labs, Inc. entered into a Strategic Advisory and Private Placement Agreement with ThinkEquity LLC for a proposed private placement of approximately $6,000,000 of the Company's securities on a best efforts basis.

10-Q filing | 41.5M shares outstanding

8-K filing: ProPhase Labs, Inc. entered into a Securities Purchase Agreement for a private placement of senior secured convertible notes and warrants, resulting in net proceeds of $2,251,343.20 from the lead investor and $500,000 from the second investor with the potential issuance of shares of common stock upon conversion of the Notes or exercise of the Warrants.

8-K filing: ProPhase Labs, Inc. entered into two identical loan agreements with Ted Karkus and an unaffiliated investor for $500,000 each, and issued 500,000 unvested warrants to purchase common stock to Mr. Karkus.

10-Q filing | 41.5M shares outstanding

10-K filing | 41.9M shares outstanding

8-K filing: ProPhase Labs, Inc. entered into a common stock purchase agreement with an equity line investor to sell up to $7,730,973 of shares of the Company's common stock, and issued 352,176 commitment shares to the investor.

10-Q filing | 23.9M shares outstanding

S-3 filing: Prophase Labs, Inc. files an S-3 registration statement to issue up to $291,612,849 in aggregate principal amount of common stock, preferred stock, warrants and/or units in one or more offerings.

10-Q filing | 18.9M shares outstanding

10-Q filing | 18.0M shares outstanding

10-K filing | 17.2M shares outstanding

10-Q filing | 17.2M shares outstanding

10-Q filing | 16.8M shares outstanding

10-Q filing | 17.2M shares outstanding

10-K filing | 15.8M shares outstanding

8-K filing: ProPhase Labs, Inc. issued an unsecured promissory note for $7.6 million to JXVII Trust and a common stock purchase warrant to JXVII, granting the right to purchase up to 76,000 shares at $9.00 per share.

8-K filing: ProPhase Labs, Inc. entered into an Asset Purchase Agreement with Stella Diagnostics Inc. and Stella DX, LLC to purchase assets related to the BE-Smart Esophageal Pre-Cancer diagnostic screening test, involving cash payment and issuance of common stock.

10-Q filing | 16.3M shares outstanding

10-Q filing | 16.0M shares outstanding

10-Q filing | 15.5M shares outstanding

10-K filing | 15.2M shares outstanding

8-K filing: ProPhase Labs, Inc. entered into a letter agreement with Justin J. Leonard providing for the payoff of an Unsecured Convertible Promissory Note, including the conversion of $600,000 of principal into 200,000 shares of common stock at $3.00 per share and the repurchase of those Conversion Shares at $5.75 per share. ($1.15M proceeds)

10-Q filing | 15.5M shares outstanding

S-3 filing: The filing is an S-3 shelf registration to register an indeterminate number of shares of common stock and preferred stock with an aggregate initial offering price not to exceed $300,000,000.

8-K filing: ProPhase Precision Medicine, Inc., a wholly-owned subsidiary of ProPhase Labs, Inc., acquired all of the issued and outstanding shares of common stock of Nebula Genomics, Inc. for approximately $14.6 million, subject to post-closing adjustments.

10-Q filing | 15.2M shares outstanding

S-3 filing: Registration statement for the potential offering of up to $75,000,000 in aggregate principal amount of common stock, preferred stock, warrants and/or units.

10-Q filing | 15.2M shares outstanding

10-K filing | 15.2M shares outstanding

8-K filing: ProPhase Labs, Inc. entered into an underwriting agreement for a public offering of 3 million shares of common stock at $12.50 per share, with net proceeds expected to be approximately $35.1 million, and granted the underwriters an option to purchase up to an additional 450,000 shares. ($37.5M proceeds)

8-K filing: ProPhase Labs, Inc. entered into a securities purchase agreement to issue and sell 550,000 shares of common stock and warrants to purchase up to 275,000 shares in a registered direct offering, with the closing expected on January 7, 2021. ($5.5M proceeds)

10-Q filing | 11.6M shares outstanding

10-Q filing | 11.6M shares outstanding

10-Q filing | 11.6M shares outstanding

10-K filing | 11.6M shares outstanding